Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Katsuhiro, Inui, Naoki, Karayama, Masato, Inoue, Yusuke, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Takeuchi, Kengo, Sugimura, Haruhiko, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322209/
https://www.ncbi.nlm.nih.gov/pubmed/28271038
http://dx.doi.org/10.1016/j.rmcr.2017.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322209/
https://www.ncbi.nlm.nih.gov/pubmed/28271038
http://dx.doi.org/10.1016/j.rmcr.2017.02.009

Ejemplares similares